PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026Molecular Metabolism0 citationsOpen Access

Oleic Acid Fuels Cisplatin-Resistant Ovarian Cancer Through FABP4-Driven Lipid Uptake

View Full Paper
AIAna Maria IsacAVAndres ValdiviaDZDidi Zha

Key Points

  • This research aims to explore how oleic acid influences growth and resistance in ovarian cancer cells resistant to cisplatin.
  • Cultured isogenic ovarian cancer cell lines in low serum with oleic acid or palmitic acid for viability assays and RNA sequencing.
  • Analyzed the effects of an oleic acid enriched diet in intraperitoneal ovarian cancer xenografts.
  • Employed FABP inhibitor to assess its impact on lipid uptake and cisplatin sensitivity.
  • Cisplatin-resistant cells showed greater viability and proliferation with oleic acid compared to sensitive cells.
  • RNA sequencing indicated oleic acid upregulated cell cycle pathways, increasing cell populations in S- and G2/M phases.
  • FABP4 inhibition both reduced tumor growth in vivo and enhanced sensitivity to cisplatin in resistant ovarian cancer cells.

Abstract

Ovarian cancer (OC) depends on lipids as fuel for metastasis and growth. We previously showed that cisplatin resistant (Pt-R) OC cells uptake higher amounts of fatty acids (FAs) compared to sensitive (Pt-S) cells, a process which facilitates cancer cell survival under cisplatin-induced oxidative stress. Isogenic pairs of Pt-S and Pt-R OC cell lines were cultured in low serum conditions supplemented with either 50 μM oleic acid (OA, unsaturated) or 50 μM palmitic acid (PA, saturated) and used for viability assays, RNA-Sequencing, and cell cycle analysis. The effects of an OA enriched diet were assessed in intraperitoneal ovarian xenografts. The FABP inhibitor BMS-309403 was used to block lipid import in vitro and in vivo . Pt-R cells were less viable than Pt-S cells under serum depletion and OA rescued starvation induced inhibition of cell proliferation, with more significant effects in Pt-R compared to Pt-S cells. RNA-sequencing showed that OA promoted upregulation of cell cycle-related pathways, including G2/M checkpoints , driven by the transcription factor E2F1 . Supplementation with OA increased S- and G2/M phase cell populations in both Pt-S and Pt-R cells (p<0.05) and E2F1 inhibition reduced OA-induced cell proliferation. An OA enriched diet promoted the growth and peritoneal dissemination of Pt-R ovarian xenografts. When co-cultured with adipocytes, Pt-R cells expressed higher levels of FA transporter proteins FABP4 and CD36 compared to sensitive cells and FABP4 expression was upregulated in paired metastatic and recurrent vs. primary human ovarian tumors (p<0.05). An FABP inhibitor sensitized OC cells to cisplatin and suppressed the in vivo growth of Pt-R xenografts and patient derived xenografts. Pt-R OC cells harbor heightened dependence on unsaturated FAs compared to Pt-S cells and upregulate key transporters to increase FAs uptake. OA supports the proliferation of Pt-R cells in vitro and in vivo and a combination of carboplatin and FABP4 inhibitor reduces OC growth in vivo. These findings suggest that lipid composition may influence therapeutic response and raise important considerations for dietary guidance in patients with cancer. • Proliferation of platinum resistant ovarian cancer cells is highly dependent on oleic acid which augmented proliferation and cell cycle related pathways leading to increased G2-M and S phase transition. • A diet rich in oleic acid stimulated intraperitoneal platinum resistant ovarian xenograft growth and upregulated key pathways involved in cell cycle progression. • Platinum resistant cancer cells and metastatic and recurrent ovarian tumors upregulate the lipid transporters FABP4 and CD36. • Pharmacological inhibition of FABP4 reversed resistance to platinum and inhibited the growth of ovarian cancer xenografts and patient derived xenografts. • Our findings point to the potential impact of dietary fat on tumor progression and resistance to treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Isac et al. (2026) studied this question.

synapsesocial.com/papers/69eb0899553a5433e34b37d8https://doi.org/10.1016/j.molmet.2026.102374
Ask AI
Helpful
Bookmark
Share
View Full Paper